“Polymeric Nanoparticle-Mediated Delivery of Oncolytic Measles Virus for Targeted Therapy in Cervical Cancer”, Pharmaceutical Communications, vol. 3, no. 1, pp. 45–53, Jun. 2024, doi: 10.55627/pharma.003.001.0887.